Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 27;17(10):sfae256.
doi: 10.1093/ckj/sfae256. eCollection 2024 Oct.

Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis

Pierre Gabai  1 , Etienne Novel-Catin  1 , Quitterie Reynaud  2   3   4 , Raphaële Nove-Josserand  2 , Solenne Pelletier  1 , Denis Fouque  1   5 , Laetitia Koppe  1   5 , Isabelle Durieu  2   3   4
Affiliations

Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis

Pierre Gabai et al. Clin Kidney J. .

Abstract

Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is a new cystic fibrosis transmembrane conductance regulator (CFTR) modulator that has transformed the respiratory prognosis of people with cystic fibrosis (pwCF). However, its impact on other organs such as the kidneys, where CFTR is expressed, remains unclear. Since pwCF are risk of both kidney disease and urolithiasis, we aimed to study the potential effects of ETI on renal function, volume status, and risk factors for urolithiasis.

Methods: This prospective, observational, single-center, before-after cohort study, involved adult pwCF eligible for ETI. The changes in plasma and urinary profiles were assessed by comparing renal function (using 2021 CKD-EPIcreatinine and 2021 CKD-EPIcreatinine-cystatin C formulas), volume status (using aldosterone/renin ratio and blood pressure), and risk factors for urolithiasis, at the time of ETI introduction (M0) and 7 months after (M7).

Results: Nineteen pwCF were included. No significant change in renal function was observed between M0 and M7 (2021 CKD-EPIcreatinine: 105.5 ml/min/1.73 m² at M0 vs. 103.3 ml/min/1.73 m² at M7; P = .17). There was a significant reduction in aldosterone level (370.3 pmol/l at M0 vs. 232.4 pmol/l at M7; P = .02) and aldosterone/renin ratio (33.6 at M0 vs. 21.8 at M7; P = .03). Among the risk factors for urolithiasis, a significant reduction in magnesuria level was found (4.6 mmol/d at M0 vs. 3.8 mmol/d at M7; P = .01).

Conclusion: These findings suggest that ETI seem to have no short-term impact on the renal function of adult pwCF and appears to correct secondary hyperaldosteronism due to excessive sweat losses. Further investigations are needed to determine the potential impact of decreased magnesuria observed under ETI therapy on the risk of urolithiasis.

Keywords: cystic fibrosis; elexacaftor/tezacaftor/ivacaftor; glomerular filtration rate; risk of urolithiasis; secondary hyperaldosteronism.

PubMed Disclaimer

Conflict of interest statement

D.F. has received speaker fees or travel support from AstraZeneca, Astellas, Lilly and Fresenius Kabi. I.D. declares an activity as a clinical trial investigator for Vertex and acknowledges having received support for conference travel from Viatris. L.K. having received grants from Fresenius Kabi, Nestlé, Lallemand, AstraZeneca and consultancy or speaker fees or travel support from AstraZeneca, Lilly, Baxter, Bayer, and Fresenius Kabi. P.G., E.N.-C., Q.R., R.N.-J., and S.P. declare no conflicts of interest.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Study flow chart.
Figure 2:
Figure 2:
Changes in creatinine levels and eGFR using 2021 CKD-EPIcreatinine and 2021 CKD EPIcreatinine-cystatin C formulas between the introduction of ETI (M0) and 7 months after (M7).
Figure 3:
Figure 3:
Changes in aldosterone levels and aldosterone/renin ratio between the introduction of ETI (M0) and 7 months after (M7).
Figure 4:
Figure 4:
Changes in magnesuria and 25-OH vitamin D levels between the introduction of ETI (M0) and 7 months after (M7).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Registre français de la mucoviscidose—Bilan des données 2022. Vaincre la Mucoviscidose. Paris. Septembre 2023.
    1. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073–80. 10.1126/science.2570460 - DOI - PubMed
    1. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008;372:415–7. 10.1016/S0140-6736(08)61162-9 - DOI - PubMed
    1. Elborn JS. Cystic fibrosis. Lancet 2016;388:2519–31. Epub 2016 Apr 29. 10.1016/S0140-6736(16)00576-6 - DOI - PubMed
    1. Crawford I, Maloney PC, Zeitlin PL et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991;88:9262–6. 10.1073/pnas.88.20.9262 - DOI - PMC - PubMed

LinkOut - more resources